Nurexone Advances Vision Restoration at ARVO 2025
NurExone Biologic Inc. presented preclinical data at the ARVO annual meeting, demonstrating that its ExoPTEN therapy restored retinal activity...
Soquelitinib Shows Promise in Atopic Dermatitis Trial
Corvus Pharmaceuticals released interim Phase 1 data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe...
UTRx Therapeutics Announces IND Submission for C-MYC mRNA Drug
UTRx Inc. submitted an Investigational New Drug (IND) application to the FDA for UTRxM1-18, a novel therapeutic targeting c-MYC...
Kriya at ARVO 2025: Vision Research
Kriya Therapeutics presented preclinical data at the ARVO Annual Meeting for KRIYA-825, a gene therapy candidate for Geographic Atrophy...
Emerging IGA Nephropathy Treatments Drive Notable Changes in Care
Spherix Global Insights’ analysis of over 2,300 patient charts reveals a global shift in IgA nephropathy (IgAN) treatment, driven...
Yamo Pharma L1-79 Shows Strong Phase 2 Autism Results
Yamo Pharmaceuticals announced positive Phase 2 trial results for L1-79, a drug targeting core autism spectrum disorder (ASD) symptoms,...
PDS Biotech Reveals Details on Universal Flu Studies at Immunology2025™
PDS Biotechnology Corporation announced preclinical data on its investigational Infectimune®-based flu vaccine at the IMMUNOLOGY2025™ Annual Meeting. Studies conducted...
Zervimesine Reduced Lesion Growth in Phase 2 Geographic Atrophy Study
Cognition Therapeutics announced topline results from its Phase 2 MAGNIFY trial of zervimesine, an oral drug for geographic atrophy...
Ashvattha Therapeutics Positive Phase 2 Results for Migaldendranib at ARVO
Ashvattha Therapeutics announced positive interim Phase 2 results for its subcutaneously administered nanomedicine, migaldendranib (MGB), designed to treat retinal...
Myriad Genetics Publishes RiskScore Study in JCO
A real-world study published in JCO Precision Oncology suggests that Myriad Genetics’ RiskScore tool, integrated into its MyRisk Hereditary...
